Press release Biocartis Group NV

Biocartis announces resignation CFO

PRESS RELEASE

REGULATED INFORMATION – INSIDE INFORMATION       
5 June 2023, 17:40 CEST

BIOCARTIS ANNOUNCES RESIGNATION CFO

Mechelen, Belgium, 5 June 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that Jean-Marc Roelandt, the Company’s Chief Financial Officer (‘CFO’)¹, has decided to resign from Biocartis for personal reasons.

Biocartis has initiated a selection process to recruit a new CFO. The Company and Mr. Roelandt have agreed that he will stay with Biocartis until 4 August 2023 to ensure a smooth transition for the Company.

--- END ---

More information:

Investor Relations Biocartis
e-mail        [e-mail]
tel         [phone]
@Biocartis_

www.linkedin.com/Biocartis

About Biocartis

With its revolutionary and proprietary Idylla platform, Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, convenient, fast and suitable for any lab. The Idylla platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster, informed treatment decisions. Idylla's continuously expanding menu of molecular diagnostic tests address key unmet clinical needs, with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal, lung and liver cancer, as well as for COVID-19, Flu, RSV and sepsis. For more information, visit www.biocartis.com or follow Biocartis on Twitter @Biocartis_ , Facebook or LinkedIn. 

Biocartis and Idylla are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.

This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.